On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Recent results from BristolMyersSquibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-MyersSquibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves BristolMyersSquibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Some results have been hidden because they may be inaccessible to you